Pfizer's first-in-class JAK inhibitor pricey for rheumatoid arthritis market

Nat Biotechnol. 2013 Jan;31(1):3-4. doi: 10.1038/nbt0113-3.
No abstract available

Publication types

  • News

MeSH terms

  • Arthritis, Rheumatoid / drug therapy*
  • Drug Costs*
  • Drug Industry*
  • Humans
  • Janus Kinases / antagonists & inhibitors*
  • National Institutes of Health (U.S.)
  • Piperidines / economics*
  • Piperidines / pharmacology
  • Piperidines / therapeutic use
  • Protein Kinase Inhibitors / economics*
  • Protein Kinase Inhibitors / pharmacology
  • Protein Kinase Inhibitors / therapeutic use
  • Pyrimidines / economics*
  • Pyrimidines / pharmacology
  • Pyrimidines / therapeutic use
  • Pyrroles / economics*
  • Pyrroles / pharmacology
  • Pyrroles / therapeutic use
  • United States

Substances

  • Piperidines
  • Protein Kinase Inhibitors
  • Pyrimidines
  • Pyrroles
  • tofacitinib
  • Janus Kinases